Cargando…

Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease

Clinical trials aiming to assess the safety and efficacy of fetal cell transplantation in Parkinson's disease rely on the hypothesis that the grafted tissue will survive and grow, restore striatal dopaminergic neurotransmission, improve the connectivity between striatum, thalamus and cortex and...

Descripción completa

Detalles Bibliográficos
Autor principal:	Politis, Marios
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098794/ https://www.ncbi.nlm.nih.gov/pubmed/21569273 http://dx.doi.org/10.1186/1741-7015-9-50

Ejemplares similares

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?
por: Politis, Marios
Publicado: (2010)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Clinical application of stem cell therapy in Parkinson's disease
por: Politis, Marios, et al.
Publicado: (2012)

Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability
por: Politis, Marios, et al.
Publicado: (2011)

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
por: Pagano, Gennaro, et al.
Publicado: (2017)

A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism
por: Niccolini, Flavia, et al.
Publicado: (2016)

Self-Image in Women with Parkinson’s Disease
por: Mathur, Soania, et al.
Publicado: (2023)

Parkinson's disease in the elderly and the comprehensive geriatric assessment
por: Lauretani, Fulvio
Publicado: (2013)

Fetal Pancreas as a Source for Islet Transplantation: Sweet Promise and Current Challenges
por: Eventov-Friedman, Smadar, et al.
Publicado: (2013)

Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
por: Yousaf, Tayyabah, et al.
Publicado: (2019)

Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease
por: Greene, Paul E., et al.
Publicado: (2021)

Serotonergic dysregulation is linked to sleep problems in Parkinson's disease
por: Wilson, Heather, et al.
Publicado: (2018)

Current status of PET imaging in Huntington’s disease
por: Pagano, Gennaro, et al.
Publicado: (2016)

Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment
por: Chandra, Avinash, et al.
Publicado: (2018)

Air pollution and sudden death risk in patients with Parkinson’s disease: Assessing the evidence to date
por: Nejm, Mariana, et al.
Publicado: (2020)

Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease
por: Schulz, Jonathan, et al.
Publicado: (2018)

The Placenta Effect: Risk Factors for Adverse Fetal Outcomes in Pregnant Dialysis Patients
por: Kattah, Andrea
Publicado: (2018)

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Understanding of skeletal deformities in Parkinson's disease
por: Baik, Jong Sam
Publicado: (2016)

Immunotherapy trials in Parkinson’s disease: challenges
por: Xiao, Bin, et al.
Publicado: (2023)

Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease
por: Niccolini, Flavia, et al.
Publicado: (2019)

Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease
por: Abdulmalik, Osheiza, et al.
Publicado: (2017)

Molecular Imaging Markers to Track Huntington’s Disease Pathology
por: Wilson, Heather, et al.
Publicado: (2017)

Testing the Protein Propagation Hypothesis of Parkinson Disease
por: Dagher, Alain, et al.
Publicado: (2018)

Hopamine as Personalized Medicine for Persons with Parkinson’s Disease
por: Noordegraaf, Marina A., et al.
Publicado: (2023)

Future of Monoclonal Antibody Therapy in Parkinson’s Disease
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Predict cognitive decline with clinical markers in Parkinson’s disease (PRECODE-1)
por: Wilson, Heather, et al.
Publicado: (2019)

Fetal origin of brain dysmaturation in congenital heart disease – Challenges and opportunities for interventions
por: Volpe, J.J.
Publicado: (2022)

Commentary on transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation
por: Ishida, Hideki
Publicado: (2022)

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?
por: Barker, Roger A., et al.
Publicado: (2016)

Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease
por: Langley, Paul C
Publicado: (2022)

Imaging of Microglia in Patients with Neurodegenerative Disorders
por: Politis, Marios, et al.
Publicado: (2012)

New Answers to Old Questions: Waitlist Versus Transplant Outcomes in the Coronavirus Disease 2019 Era
por: Klassen, David
Publicado: (2020)

Evaluating whole slide imaging: A working group opportunity
por: Treanor, Darren, et al.
Publicado: (2015)

The pons and human affective processing — Implications for Parkinson's disease
por: Huot, Philippe
Publicado: (2015)

Novel gene (TMEM230) linked to Parkinson’s disease
por: Olszewska, Diana A., et al.
Publicado: (2016)

The understanding of Parkinson's disease through genetics and new therapies
por: Uwishema, Olivier, et al.
Publicado: (2022)

Targets for astrocyte-based treatments of Parkinson’s disease (PD)
por: Parmar, Malin
Publicado: (2022)

Sex Differences in Parkinson’s Disease: From Bench to Bedside
por: Russillo, Maria Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8a95g820f7pgju54knq9td87hd